NOTICE OF TECHWATCH SYSTEM TRANSITION: BARDA has transitioned to new portal for stakeholder engagement, including a new TechWatch Meeting Request submission form. The new submission portal has launched and can be access on the BARDA Digital Resources Portal.
TECHWATCH IS BACK!

REQUEST A TECHWATCH MEETING WITH BARDA AND INTERAGENCY PARTNERS

BARDA is opening TechWatch again to all threat areas; including COVID-19 technologies! Submit your TechWatch Request now for the opportunity for the U.S. government experts to discuss your product, technology or capabilities and explore potential partnering opportunities.

OVER A DECADE OF INDUSTRY ENGAGEMENT

CoronaWatch Dashboard

Corona Watch Response

760+

COVID-19 CoronaWatch Virtual Market Research Meetings with innovative companies

Corona Watch Response

 

COVID-19 CoronaWatch requests from every state in the USA

Corona Watch Response

30+

Countries - CoronaWatch Meeting Requests from Around the Globe

TechWatch Dashboard

TechWatch Response

1,335+

TechWatch Market Research Meetings with innovative companies

TechWatch Response

 

TechWatch requests from every state in the USA

TechWatch Response

70+

Countries - TechWatch Meeting Requests from Around the Globe

Now coming together under a streamlined TechWatch Process

seeking submissions

The U.S. government (USG) provides a portal as a single point of entry for the submission of meeting requests from interested stakeholders with promising MCM products, technologies, and capabilities.

seeking submissions

The USG seeks information from stakeholders on available medical countermeasures in development. We are particularly interested in products, technologies, and capabilities that have progressed into or beyond clinical trials, have established large-scale cGMP manufacturing capability, or utilize an approved platform. Information regarding diagnostics, therapeutics, vaccines, and other products, technologies, or capabilities relevant to respond to public health emergencies are sought.

We ask for a brief description of your product technology, or capability, accompanied by a slide deck, manuscript, publications, or other non-confidential information of your choosing. Please note while we use information you present as market research; submission is no guarantee of a meeting or funding and your submission will be shared with our teams involved in medical countermeasure research and development. Only USG officials are invited to join TechWatch meetings and are bound by law to maintain the confidentiality of what is presented and discussed.

  • Relevant to the U.S. government medical countermeasure research and development efforts and/or Emerging Infectious Disease rapid response capabilities
  • Utilize an already-approved platform, have non-clinical data suggesting efficacy, and/or have significant manufacturing capability
  • Fully owned or licensed by your organization (you have full IP rights and/or freedom to operate)

TechWatch Meeting Process

Typically, TechWatch meeting submissions are reviewed within 30 days of submission. If your product, technology, or capability aligns with our program priorities it is likely we will contact you to set up a TechWatch meeting within an additional 30 days. Please note due to the complexities and priorities related to the pandemic slight delays in timing may result.

SELECT A STEP TO LEARN MORE

Before submitting a meeting request, you must Login. If you have not visited this site before, please take a few moments to Register.

Submit basic product information or view/update existing submissions. Upon successful submission, you will receive a confirmation email with a Tracking ID (e.g.: BDR-TW-2022-00001).

We will evaluate your request and route it to the most appropriate resource within the federal government. 
*See BARDA TechWatch Evaluation Areas for BARDA’s assessment areas.

We will schedule a targeted or broad meeting.

OR

A meeting is not scheduled, but your technology is retained for future reference.

Submit

Evaluate & Prioritize*

Notification

Before You Submit:

  • BARDA is currently evaluating TechWatch Meeting Requests for specific areas. View the list: BARDA TechWatch Evaluation Areas.
  • These requests are for market research purposes only and are not considered submissions for potential funding.
  • Do not submit multiple requests for the same product, technology, or capability.

Before submitting a meeting request, you must Login. If you have not visited this site before, please take a few moments to Register.

Submit

Submit basic product information or view/update existing submissions. Upon successful submission, you will receive a confirmation email with a Tracking ID (e.g.: BDR-TW-2022-00001).

Evaluate & Prioritize*

We will evaluate your request and route it to the most appropriate resource within the federal government. 
*See BARDA TechWatch Evaluation Areas for BARDA’s assessment areas.

Notification

We will schedule a targeted or broad meeting.

OR

A meeting is not scheduled, but your technology is retained for future reference.

Before You Submit:

  • These requests are for market research purposes only and are not considered submissions for potential funding.
  • We are only reviewing meeting requests related to COVID-19.
  • Do not submit multiple requests for the same product or technology.

BARDA TECHWATCH EVALUATION AREAS

Explore the TechWatch submission threats and areas BARDA is actively assessing.

Threat Category
Acute Radiation SyndromeRad/Nuc
Anthrax (Bacillus anthracis)Biological
Antimicrobial Resistance / Antibiotic Susceptibility TestsBiological
Biodosimetry Self-Assessment ToolsRad/Nuc
BiotoxinsChemical
Blister Agents/VesicantsChemical
Blood Agents (cyanide, H2S)Chemical
Blood Products and Blood-derived ProductsRad/Nuc
Botulism (Clostridium botulinum toxin)Biological
Brucellosis (Brucella species)Biological
Burn/Blast InjuryRad/Nuc
Choking/Lung/Pulmonary AgentsChemical
Chronic Effects of Radiation ExposureRad/Nuc
Coronaviruses (e.g., SARS, MERS, COVID-19)Biological
Epidemic/Pandemic InfluenzaBiological
Glanders (Burkholderia mallei)Biological
Incapacitating AgentsChemical
InfluenzaBiological
Internal Contamination (radiation/decorporation of isotopes)Rad/Nuc
Meliodosis (Burkholderia pseudomallei)Biological
Nerve AgentsChemical
Patient decontaminationChemical
Plague (Yersinia pestis)Biological
Smallpox (variola major)Biological
Trauma therapeuticsRad/Nuc
Tularemia (Francisella tularensis)Biological
Viral hemorrhagic fevers (filoviruses, arenaviruses, other viruses in order Bunyavirales, flaviviruses)Biological
Viruses, other RNA (flaviviruses, alphaviruses, picornaviruses, paramyxoviruses, Bunyavirales order)Biological
Program Category
BARDA VenturesDRIVe
Beyond the NeedleDRIVe
Bringing Laboratory Testing to the HomeDRIVe
Digital Health Tools for Pandemic PreparednessDRIVe
DRIVe Start efforts/challengesDRIVe
Host Based DiagnosticsDRIVe
Host Based TherapeuticsDRIVe
Infection Severity and Solving SepsisDRIVe
ReDIRECTDRIVe

Threat Category
Caustics (Acids)Chemical
Epsilon Toxin of Clostridium perfringensBiological
Food Safety Threats (e.g., Salmonella species, Escherichia coli O157:H7, Shigella)Biological
Long-Acting AnticoagulantsChemical
MetalsChemical
Organic SolventsChemical
Psittacosis (Chlamydia psittaci)Biological
Q Fever (Coxiella burnetti)Biological
Ricin Toxin from Ricinus communis (castor beans)Biological
Riot Control Agents/Tear GasChemical
Staphylococcal enterotoxin BBiological
Surface decontamination (biological or chemical)Biological
Toxic AlcoholsChemical
Typhus fever (Rickettsia prowazekii)Biological
Water Safety Threats (e.g., Vibrio cholerae, Cryptosporidium parvum)Biological
Zika virus diseaseBiological
Program Category
ENACTDRIVe
Home DxDRIVe
Immune ChipDRIVe
Next-Generation Sequencing (NGS)DRIVe
Rapidly Deployable CapabilitiesDRIVe
  • Gain visibility for your solution
  • Receive feedback from USG experts
  • Hear techniques and strategies for addressing technical and regulatory challenges
  • Get insight on how your solution could fit within the Government
  • Better prepare you for a formal proposal submission

Note: TechWatch submissions are not considered for potential funding

  • All submissions are voluntary and are for information only. However, submitting complete information may facilitate request routing.
  • Review submitted request by Logging in and select your existing meeting request.
  • If you have additional questions about the TechWatch program, please contact us: TechWatchInbox@hhs.gov.

Note: Entities with a White Paper or proposal currently under review for any ASPR solicitation are not eligible to schedule a TechWatch meeting related to that submission. If you have concerns regarding your eligibility, please raise them with our TechWatch team as soon as possible.

  • Public Law passed by Congress and signed by the President, December 2006 (PAHPA, PAHPRA, PAHPAIA, 21st Century Cures)
  • Active outreach and scouting to improve the Nation’s public health and medical preparedness and response capabilities
  • Web based infrastructure to facilitate outreach and meetings with stakeholders
  • Key engagement function during routine and emergency operations